Finerenone Shows Broader Evidence Across Various CKD Types, Says Hiddo Heerspink, PhD
Audio narration · Coming soon
Hiddo Heerspink, PhD, highlights new data on finerenone's effectiveness in treating chronic kidney disease (CKD) across different types, including type 1 diabetes, FSGS, and IgA nephropathy. The discussion also addresses ongoing questions regarding the sequencing of CKD therapies. This update reflects expanding research on finerenone's role in managing diverse CKD conditions.
Why this matters
PRISM scored this story 55/100 for interest.
Originally published by gnews